Zoetis Issues 2026 Adj EPS Guidance of $6.15-$6.25
ZTS is trading near its 52-week low of $71.47 (0.7% above the low).
Summary
Zoetis provided its first 2026 adjusted EPS outlook of $6.15 to $6.25. The stock is trading near its 52-week low of $71.47, down sharply from a high of $160.48, reflecting a challenging year. This guidance follows a Q1 operational revenue decline and a $450 million IRS tax liability disclosed in May. The midpoint of $6.20 offers a concrete baseline for the year, but the market will weigh it against the recent VitalRADS acquisition and the Australian regulatory review of the Neogen Genomics deal.
At the time of this announcement, ZTS was trading at $72.00 on NYSE in the Life Sciences sector, with a market capitalization of approximately $31.2B. The 52-week trading range was $71.47 to $160.48. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.